MBX Biosciences (MBX) Guggenheim Inaugural Global Healthcare Innovation Conference summary

Company overview and financial position

• Clinical-stage biopharma focused on precision endocrine peptides (PEP) with validated human data.

• Raised $250 million from Series C and IPO, totaling $400 million, with $277.1 million cash on hand and runway to mid-2027.

• Aims to accelerate product development, expand pipeline, and prepare for commercialization.

Pipeline and upcoming catalysts

• Lead program MBX 2109 is in phase 2 for hypoparathyroidism, with top-line results expected Q3 2025.

• MBX 1416, a long-acting GLP-1 antagonist for post-bariatric hypoglycemia, will present phase 1 results in January 2025.

• Obesity candidate MBX 4291, a GLP-1/GIP coagonist, targets once-monthly dosing; IND submission planned for Q2 2025.

MBX 2109: Clinical differentiation and market opportunity

• Designed as a once-weekly PTH prodrug with orphan drug designation in the U.S.

• Offers stable PK profile, aiming for better efficacy and safety versus daily competitors like Yorvipath.

• Phase 2 trial is 12 weeks, fully placebo-controlled, with titration to optimal dose and a composite endpoint at 12 weeks.

• Device is a single-use, pen-like injector for weekly dosing, differentiating from competitors.

• Strong patient interest and rapid enrollment, with a two-year extension study post-trial.